FLT3 and hematologic disorder: Sunitinib has been proposed as a potential candidate to treat FLT3-driven hematological malignancies (Ikezoe et al., 2006), an alteration that is present in the SEM cell line (Brown et al., 2005; Gu et al., 2011).